Jazz Pharmaceuticals NASDAQ: JAZZ is counting on new drug launches, pipeline studies and acquisitions to sustain growth across its sleep, epilepsy and oncology businesses, President and CEO Renee Gala said at an investor event.
Gala pointed to third-quarter revenue of $1.24 billion, up 10% from a year earlier, and the company’s raised 2026 revenue guidance of $4.775 billion to $4.85 billion. She said performance across all three commercial portfolios contributed to the increase.
Ziihera Launch and Pipeline
Gala said the launch of Ziihera in first-line HER2-positive metastatic gastroesophageal adenocarcinoma, or GEA, was off to a strong start following its approval at the end of August. The underlying study showed median overall survival of 27 months with the triplet regimen, she said.
Jazz has projected $3 billion to $5 billion in peak sales for Ziihera across its development programs. Gala said more than three-quarters of physicians surveyed indicated an intent to prescribe the drug. In September, average daily vial use increased 40%, while the number of new accounts ordering the product rose threefold, she said.
Gala estimated that 3,000 to 4,000 patients are addressable candidates for the GEA treatment. She said Jazz expects patients to receive prescriptions as they present over the year, rather than through an immediate surge in demand. She expects the treatment to become standard of care, though she said changing prescribing practices in community settings will require work.
On a potential colorectal cancer opportunity for Ziihera, Gala said discussions with regulators were ongoing and that she was encouraged by the data, but did not provide a filing timeline. She also said a metastatic breast cancer study is expected to read out at the end of 2027 or early 2028.
MODEYSO and Actio Studies
Jazz expects the ACTION study of MODEYSO in first-line glioblastoma to read out in the first half of next year, Gala said. The study serves as both a confirmatory and frontline trial. She identified a potential first-line approval, treatment duration and further penetration into institutions and community settings as possible growth drivers.
Jazz has estimated MODEYSO’s peak U.S. sales potential at $500 million. The drug came through the acquisition of Chimerix, which Gala said cost less than $900 million.
The company also plans to present data later this quarter from its Actio program for KCNT1 epilepsy. Gala said investors should focus on seizure-control data from a subset of patients. She described earlier open-label data from an expanded-access setting as promising and said discussions with the Food and Drug Administration were progressing positively.
John Bluth, Jazz’s head of investor relations, said the ongoing KYRON trial of ABS-1230 could support registration. It examines patients over a 12-week period and includes a placebo-controlled arm. The company expects to present some data from the trial at a conference in early December, he said.
Sleep Franchise and Competition
Gala said the company’s Xywav business grew 12% year over year in the third quarter and added a net 425 patients: 325 with idiopathic hypersomnia and 100 with narcolepsy. Xywav had 17,550 patients at the end of the quarter, with roughly one-third treated for idiopathic hypersomnia and two-thirds for narcolepsy, she said.
Asked about competition from newly approved orexin treatments for narcolepsy type 1, Gala said they could delay some new patient starts on oxybate therapy. She expects the treatments to be complementary over time, noting that orexins do not target disrupted nighttime sleep. Gala also said Jazz had seen little, if any, impact on Xywav from generic competition.
On longer-term guidance, Gala did not commit to providing a three- to five-year forecast. She said Jazz would provide annual revenue guidance at its year-end earnings update in February and decide whether to offer product- or franchise-specific figures. “Execution says a lot,” she said.
About Jazz Pharmaceuticals (NASDAQ:JAZZ)
Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing medicines for serious diseases, particularly in neuroscience and oncology. Founded in 2003, the company is headquartered in Dublin, Ireland, and serves patients in the United States and international markets. Its products include treatments for sleep disorders and seizure conditions, such as Xywav, Xyrem, Sunosi and Epidiolex. Jazz also offers medicines used in cancer care, including Zepzelca, Vyxeos and Rylaze, as well as Defitelio for a serious complication following stem cell transplantation.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Jazz Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.
While Jazz Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.